FDA Approval Pathways for Nanorobotic Combination Products: Pre-Clinical Safety and IND Filing

Bringing an untethered surgical or therapeutic nanorobot to human clinical trials requires satisfying comprehensive toxicology, biodistribution, and clearance benchmarks under ISO 10993 and FDA 21 CFR Part 3 regulations.

1. Pharmacokinetics and Biodistribution (ADME-Tox)

Regulatory dossiers must precisely characterize Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME-Tox). For metallic microrobots (e.g., nickel, platinum, or cobalt alloys), heavy metal leaching poses severe nephrotoxicity risks. Gold, silica, and bio-compatible iron oxides are preferred regulatory substrates, requiring inductively coupled plasma mass spectrometry (ICP-MS) to quantify organ retention over 90-day animal clearance studies.

2. Immunogenicity and Complement Activation

Nanorobotic surfaces must be thoroughly evaluated for complement activation-related pseudoallergy (CARPA). Nanoparticles can trigger non-IgE-mediated hypersensitivity reactions in cardiovascular beds. In vitro human serum assays measuring C3a and C5a activation fragments are mandatory precursors to filing an Investigational New Drug (IND) application with the FDA.